Advanced BioDesign's ABD-3001 Trial Shows Promising Results in AML Treatment

Advanced BioDesign's ABD-3001 Trial Shows Promising Results in AML Treatment

Alexandra Rossi
2 min read

Advanced BioDesign's ABD-3001 Trial Shows Promising Results in AML Treatment

Advanced BioDesign's ODYSSEY trial, the first Phase I/II study in France targeting acute myeloid leukaemia (AML), has exhibited encouraging initial results with its drug candidate ABD-3001 (Sefaldin). The drug, a suicide inhibitor of the enzyme ALDH1, has demonstrated efficacy in over 65% of treated patients, with no significant safety concerns. Preliminary data indicates that ABD-3001 effectively inhibits ALDH1A1 activity and JNK protein phosphorylation from the first dose. The trial is transitioning into its second stage, where patients will undergo treatment over three cycles to further assess the drug's efficacy and impact on quality of life, as well as seeking compassionate use for select patients who displayed significant improvement after a single dose.

Key Takeaways

  • ODYSSEY trial is the first Phase I/II study in France focusing on AML treatment.
  • Advanced BioDesign's ABD-3001 demonstrates preliminary efficacy in over 65% of AML patients.
  • ABD-3001, a suicide inhibitor of ALDH1, exhibits biological activity from the initial dose.
  • Sefaldin (ABD-3001) is safe and well-tolerated with no significant safety issues in AML patients.
  • The trial's second stage will evaluate multiple treatment cycles to confirm ABD-3001's efficacy.


The promising results of Advanced BioDesign's ODYSSEY trial for ABD-3001 in treating AML could significantly impact the biotech industry and healthcare. The high efficacy and safety profile of ABD-3001, targeting ALDH1, implies a potential paradigm shift in AML treatment. This development could lead to accelerated regulatory approvals and market entry, benefitting patients and investors. However, broader implications include increased scrutiny on similar drugs in development and potential shifts in investment towards targeted therapies. Successful trials could redefine treatment protocols and improve patient outcomes in the long term, while influencing stock prices and R&D strategies in the short term in the biotech sector.

Did You Know?

  • Acute Myeloid Leukaemia (AML): A type of cancer affecting the blood and bone marrow, characterized by the rapid growth of abnormal white blood cells, which accumulate and interfere with the production of normal blood cells. AML is prevalent in adults.
  • Suicide Inhibitor: A type of enzyme inhibitor that forms a covalent bond with the enzyme, permanently deactivating it. The term "suicide" refers to the irreversible nature of the inhibition, where the inhibitor is consumed in the process of inhibiting the enzyme.
  • ALDH1A1: An enzyme belonging to the aldehyde dehydrogenase family, which plays a crucial role in detoxifying aldehydes and is involved in cellular processes such as differentiation, proliferation, and apoptosis. Inhibiting ALDH1A1 can potentially affect cancer cell survival and proliferation.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines. The cover photo is computer generated art for illustrative purposes only; not indicative of factual content. If you believe this article infringes upon copyright rights, please do not hesitate to report it by sending an email to us. Your vigilance and cooperation are invaluable in helping us maintain a respectful and legally compliant community.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings